Recent studies demonstrate that specific probiotics (e.g., Limosilactobacillus reuteri DYNDL22M62) mitigate AD inflammation through dual mechanisms: restoration of skin microbial diversity; suppression of TSLP production, reducing Th2 cytokine levels. The gene discussed is TSLP; the disease is Alzheimer disease.